FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 353 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR TRACERx EVO, a new programme to transform lung cancer research November 9, 2022 Our COVID-19 Response: How GreaterGood Is Making An Impact During The... April 23, 2020 New Approach May Help People with Cancer Better Manage Depression, Pain,... May 14, 2024 Sofi Leota Was Diagnosed With Breast Cancer At 23. Two Years... July 23, 2020 Load more HOT NEWS A Combination of Trifluridine-Tipiracil Plus Bevacizumab Results in Longer Overall Survival... Stopping the spread: A revolution in how we think about metastasis Limited Effect of Endocrine Therapy on Distant Metastasis-Free Interval in Patients... Combo of Ribociclib, Letrozole Improves Survival in Advanced Breast Cancer
